If you have been reading about HPLC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-01. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
=== EC 1.11.2 Peroxygenase === EC 1.11.2.1: unspecific peroxygenase EC 1.11.2.2: myeloperoxidase EC 1.11.2.3: plant seed peroxygenase EC 1.11.2.4: fatty-acid peroxygenase EC 1.11.2.5: 3-methyl-L-tyrosine peroxygenase EC 1.11.2.6: L-tyrosine peroxygenase
Symmetrical selenides are usually prepared by alkylation of alkali metal selenide salts, e.g. sodium selenide. Unsymmetrical selenides are prepared by alkylation of selenoates. These compounds typically react as nucleophiles, e.g. with alkyl halides (R'−X) to give selenonium salts [RR'R"Se]+X−. Divalent selenium can also interact with soft heteroatoms to form hypervalent selenium centers. They also react in some circumstances as electrophiles, e.g. with organolithium reagents (R'Li) to the ate complex R'RRSe−Li+. Selenoxides (R−Se(=O)−R) are the selenium equivalents of sulfoxides. Most are unstable, undergoing the selenoxide elimination, but can be notionally oxidized to selenones R−Se(=O)2−R, the selenium analogues of sulfones. Selenenic acid (R−Se−OH) are intermediates in the oxidation of selenols. They occur in some selenoenzymes, such as glutathione peroxidase. Seleninic acids (R−Se(=O)−OH) are analogues of sulfinic acids. Selenonic acids (R−Se(=O)2−OH) are analogues of sulfonic acids. Peroxyseleninic acids (R−Se(=O)−OOH) catalyse epoxidation reactions and Baeyer–Villiger oxidations. Selenuranes are hypervalent organoselenium compounds, formally derived from the tetrahalides such as SeCl4. Examples are of the type Ar−SeCl3. The chlorides are obtained by chlorination of the selenenyl chloride. Seleniranes are three-membered rings (the parent compound is selenirane or selenacyclobutane C2H4Se) related to thiiranes but, unlike thiiranes, seleniranes are kinetically unstable, extruding selenium directly (without oxidation) to form alkenes.
In June 2023, ELEVIDYS (Delandistrogene moxeparvovec) was approved by the FDA for use in 4-5-year-old boys with mutations in the DMD gene. The FDA granted accelerated approval to ELEVIDYS, which requires that the product be further studied to verify its clinical benefit. In June 2024, the U.S. Food and Drug Administration expanded approval of delandistrogene moxeparvovec to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. The FDA granted traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients.
Sources: en.wikipedia.org
=== Bone tumors === Benign tumors of bone can be similar macroscopically and require a combination of a clinical history with cytogenetic, molecular, and radiologic tests for diagnosis. Three common forms of benign bone tumors with are giant cell tumor of bone, osteochondroma, and enchondroma; other forms of benign bone tumors exist but may be less prevalent.
==== Extraterrestrial ==== PAHs are prevalent in the interstellar medium (ISM) of galaxies in both the nearby and distant Universe and make up a dominant emission mechanism in the mid-infrared wavelength range, containing as much as 10% of the total integrated infrared luminosity of galaxies. PAHs generally trace regions of cold molecular gas, which are optimum environments for the formation of stars. NASA's Spitzer Space Telescope and James Webb Space Telescope include instruments for obtaining both images and spectra of light emitted by PAHs associated with star formation. These images can trace the surface of star-forming clouds in our own galaxy or identify star forming galaxies in the distant universe. In June 2013, PAHs were detected in the upper atmosphere of Titan, the largest moon of the planet Saturn.
On 2 May, the Jordanian Air Force led an operation called "Operation Jordanian Deterrence", in the cities of Shahba, Al-Kafr, Arman and Al-Anat, controlled by the Druze militias, to counter border drug trafficking, in the city of Shahba, the Jordanian Air Force bombed the former State Security branch. On the same day the Syrian government also operated against drug trafficker. On 3 May, the National Guard published a statement where they condemned the Jordan's operation. The reason for the condemnation was the lack of coordination between Jordanian government and the National Guard.. On the same day a rebel armed group attacked Syrians positions, the attacks were similar to those of the National Guard. On 4 May, the National Guard targeted security posts in Rimat Hazem and Walgha. On 5 May, the National Guard's 501st Battalion (Hamza Knights) clashed with the Syrian Armed Forces. On 6 May, retired Jordanian military analyst, Major General Abu Nowar, told Al Jazeera English that the airstrikes were a deterrent to drug cartels, as well as a warning to external actors—such as Israel and Israel-allied elements in Suwayda—seeking to capitalize on the power struggle. On 9 May, two inner faction of the National Guard, the Saraya al-Jabal faction and the Jala Abu Daqqa faction, clashed with each other, the clashes began when Saraya al-Jabal arrested members of the Jala Abu Daqqa faction after they were accused of vehicle theft.
Federal Government systems for the electronic exchange of clinical health information. In 1999, it was identified by the HL7 Standards Development Organization as a preferred code set for laboratory test names in transactions between health care facilities, laboratories, laboratory testing devices, and public health authorities.
Sources: en.wikipedia.org
=== Graft-versus-host disease === Due to its immunosuppressant activity, rapamycin has been assessed as prophylaxis or treatment agent of graft-versus-host disease (GVHD), a complication of hematopoietic stem cell transplantation. While contrasted results were obtained in clinical trials, pre-clinical studies have shown that rapamycin can mitigate GVHD by increasing the proliferation of regulatory T cells, inhibiting cytotoxic T cells and lowering the differentiation of effector T cells.
==== Insurance ==== The transgender population has faced an increased burden of disease due to the lack of gender affirming coverage by insurance. Compared to the cisgender population, the transgender community has a lower insurance rate and faces obstacles with insurance (both private and public) denying coverage for many of their healthcare needs. According to the United States Transgender Survey (USTC), 20% of the transgender community reported insurance coverage for gender affirming care being partially covered or not being covered at all. Without insurance coverage, the transgender community is left with numerous out of pocket costs. The lack of insurance coverage denies these patients their healthcare needs and creates financial insecurity. These challenges with insurance create a decrease in healthcare outreach by the transgender community due to the costs. According to the United States Transgender Survey (USTS), 37.6% of the transgender community reported missing or avoiding preventative screenings and healthcare visits due to the costs This creates an increased burden of disease, and statistics show a higher rate of mental health conditions, poor physical health, and respiratory conditions, such as asthma. Besides the toll on this community's health and financial stability, insurers also refuse to change their records to reflect the true nature of the patient. Many health insurance companies have refused to change the individual's name and gender on their records. This creates another obstacle for this community to receive care while feeling accepted.
== Prevention == Dehiscence can be prevented through adequate tissue undermining to reduce stress on the wound edges, avoiding heavy lifting and speeding healing through adequate nutrition, controlling diabetes, and avoiding certain medications such as corticosteroids. Sterile strips may also be used to cover skin sutures for up to a week.
=== In alchemy === Alchemy used the great chain as the basis for its cosmology. Since all beings were linked into a chain, so that there was a fundamental unity of all matter, the transformation from one place in the chain to the next might, according to alchemical reasoning, be possible. In turn, the unit of the matter enabled alchemy to make another key assumption, the philosopher's stone, which somehow gathered and concentrated the universal spirit found in all matter along the chain, and which ex hypothesi might enable the alchemical transformation of one substance to another, such as the base metal lead to the noble metal gold.
====== Stimulation of beta-defensin production ====== SeV is a very effective stimulant of expression of human beta-defensin-1 (hBD-1). This protein is a member of the beta-defensin family of proteins that bridges innate and adaptive immune responses to a pathogen infection. In response to SeV infection, the production of hBD-1 mRNA and protein increases 2 hours after exposure to the virus in purified plasmacytoid dendritic cells or in PBMC.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.